Atlas Trials

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Clinical trial NCT06222944 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06222944
Sponsor
Peking University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Gastric CancerAdenocarcinoma of Esophagogastric Junction
Start date
2024-02-25
Primary completion
2025-08-25
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.